Next Article in Journal
Mutual Balance between Vasohibin-1 and Soluble VEGFR-1 in Endothelial Cells
Next Article in Special Issue
Spectrophotometric Determination of Metoprolol Tartrate in Pharmaceutical Dosage Forms on Complex Formation with Cu(II)
Previous Article in Journal
Prediction of Positions of Active Compounds Makes It Possible To Increase Activity in Fragment-Based Drug Development
Previous Article in Special Issue
Fluorescent β-Blockers as Tools to Study Presynaptic Mechanisms of Neurosecretion
Pharmaceuticals 2011, 4(5), 770-781; doi:10.3390/ph4050770
Review

The Role of Carvedilol in the Treatment of Dilated and Anthracyclines-Induced Cardiomyopathy

1,* , 1,2, 1,3, 1, 1, 4 and 5
Received: 4 March 2011; in revised form: 11 May 2011 / Accepted: 19 May 2011 / Published: 24 May 2011
(This article belongs to the Special Issue Betablockers)
View Full-Text   |   Download PDF [170 KB, uploaded 24 May 2011]   |   Browse Figure
Abstract: Although chronic sympathetic activation provides inotropic and chronotropic support to the failing heart, such activation may also have deleterious effects, including the direct cardiotoxic effects of catecholamines, activation of the renin-angiotensin-aldosterone system and an increase in myocardial oxygen demand. These observations indicate that β-blockade might be beneficial in the treatment of heart failure resulting from dilated cardiomyopathy or ischaemic heart disease. Carvedilol is a non-selective β-blocker acting on β1-, β2-, and α1-adrenoceptors. It possesses potent anti-oxidant and anti-apoptotic properties, along with neuroprotective, vasculoprotective, cardioprotective effects, and it has reduced overall mortality in patients with heart failure in controlled clinical trials. Its role in treating cardiomyopathy requires focus. The fact that anthracyclines are cardiotoxic seriously narrows their therapeutic index in cancer therapy. The cardiotoxic risk increases with the cumulative dose and may lead to congestive heart failure and dilated cardiomyopathy in adults and in children. This review focuses on recent research regarding the beneficial effects of carvedilol in the treatment of dilated cardiomyopathy and to revisit the available evidence on the cardioprotection of carvedilol when associated with anthracycline and to explain the mechanisms underlying the benefits of their co-administration.
Keywords: carvedilol; cardiomyopathy; cardioprotection carvedilol; cardiomyopathy; cardioprotection
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Watanabe, K.; Arozal, W.; Sari, F.R.; Arumugam, S.; Thandavarayan, R.A.; Suzuki, K.; Kodama, M. The Role of Carvedilol in the Treatment of Dilated and Anthracyclines-Induced Cardiomyopathy. Pharmaceuticals 2011, 4, 770-781.

AMA Style

Watanabe K, Arozal W, Sari FR, Arumugam S, Thandavarayan RA, Suzuki K, Kodama M. The Role of Carvedilol in the Treatment of Dilated and Anthracyclines-Induced Cardiomyopathy. Pharmaceuticals. 2011; 4(5):770-781.

Chicago/Turabian Style

Watanabe, Kenichi; Arozal, Wawaimuli; Sari, Flori R.; Arumugam, Somasundaram; Thandavarayan, Rajarajan A.; Suzuki, Kenji; Kodama, Makoto. 2011. "The Role of Carvedilol in the Treatment of Dilated and Anthracyclines-Induced Cardiomyopathy." Pharmaceuticals 4, no. 5: 770-781.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert